Press Releases

Our press releases

• Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002 Nov 19 2020
• BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS Nov 13 2020
• Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020 Nov 6 2020
• Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers Oct 22 2020
• Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Sep 9 2020
• BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Aug 14 2020
• Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia Aug 13 2020
• Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020 Aug 10 2020
• Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting May 29 2020
• BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS May 15 2020